Current Trastuzumab News and Events

Current Trastuzumab News and Events, Trastuzumab News Articles.
Sort By: Most Relevant | Most Viewed
Page 1 of 7 | 261 Results
Statins may protect the heart from chemotherapy treatment of early breast cancer
Women who take statins, the common cholesterol-lowering medication, during chemotherapy with anthracyclines for early-stage breast cancer are half as likely to require emergency department visits or hospitalization for heart failure in the 5 years after chemotherapy. (2021-01-06)

Common drug may protect hearts from damage caused by breast cancer chemotherapy
New research from UHN's Peter Munk Cardiac Centre (PMCC) shows statins, commonly prescribed to lower cholesterol and reduce the risk of heart disease and stroke, may also protect the heart from damaging side-effects of early breast cancer treatment. (2021-01-06)

One mouse at a time: new approach to testing potential drugs for children's cancers
Researchers have developed a way of testing potential drugs for children's cancers so as to take account of the wide genetic diversity of these diseases. instead of conventional testing designs, which use multiple mice as models for rare children's cancers, analysis had revealed that it was possible to evaluate them on a single mouse, which could accelerate the development of better treatments. The research is presented at the 32th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. (2020-10-21)

Oncotarget: NRXN1 as a novel potential target for small cell lung cancer
The cover for issue 39 of Oncotarget features Figure 4, ''Apoptosis assay of NRXN1-targeted ADC at IC50 dose calculated by growth inhibition curves,'' by Yotsumoto, et al. which reported that the authors identified transmembrane proteins overexpressed specifically in SCLC with little or no expression in normal tissues and decided to focus on the cell adhesion molecule neurexin-1. (2020-09-30)

Opening an autophagy window as the apoptosis door starts to close
Tokyo Medical and Dental University (TMDU) researchers have successfully attached the cancer cell-targeting antibody Trastuzumab to a previously reported supermolecule that induces autophagic cell death. The antibody-drug conjugate (ADC) selectively targeted HER2-overexpressing cancer calls and reduced cell viability at lower concentrations than free supermolecule drug. It is hoped that the ADC will provide a targeted autophagic death route for treating apoptosis resistant cancer cells in vivo, and ultimately provide an alternate approach in the clinic. (2020-09-24)

Drug-induced interstitial lung disease in breast cancer patients
Drug-induced Interstitial Lung Disease in Breast Cancer Patients: A Lesson We Should Learn from Multi-Disciplinary Integration Announcing a new article publication for BIO Integration journal. In this case report the authors Zijun Zhao, Zhanghai He, Hongyan Huang, Jiewen Chen, Shishi He, Ailifeire Yilihamu and Yan Nie from Sun Yat-sen University, Guangzhou, China consider drug-induced interstitial lung disease in breast cancer patients. (2020-07-27)

Yale Cancer Center study validates combination therapy for aggressive endometrial cancer
Yale Cancer Center (YCC) scientists have found that combining the targeted drug trastuzumab with chemotherapy significantly improves survival rates for women with a rare, aggressive form of endometrial cancer. These results may help to change the standard of care worldwide for the disease. The findings are published today in the journal Clinical Cancer Research. (2020-06-29)

Oncotarget: Second line trastuzumab emtansine following horizontal dual blockade
Volume 11, Issue 22 of Oncotarget reported that despite relevant medical advancements, metastatic breast cancer remains an incurable disease. (2020-06-03)

Trastuzumab achieves slight reduction in recurrence for women with HER2-positive DCIS
The addition of the monoclonal antibody therapy Trastuzumab to radiotherapy did not reach the protocol objective of a 36% reduction in the ipsilateral breast tumor recurrence rate for women with HER2-positive ductal carcinoma in situ (DCIS) on the NRG Oncology clinical trial NSABP B-43. The trial did find a statistically non-significant, modest (19%) reduction in the rate of recurrence among women that received trastuzumab, but this difference was not statistically significant. (2020-05-29)

Trastuzumab combined with trimodality treatment does not improve outcomes for patients
Results of the NRG Oncology clinical trial RTOG 1010 indicated that the addition of the monoclonal antibody trastuzumab to neoadjuvant trimodality treatment did not improve disease-free survival (DFS) outcomes for patient with HER2 overexpressing local and locally advanced esophageal adenocarcinoma. (2020-05-29)

Experiments in mice and human cells shed light on best way to deliver nanoparticle therapy for cancer
Researchers in the cancer nanomedicine community debate whether use of tiny structures, called nanoparticles, can best deliver drug therapy to tumors passively -- allowing the nanoparticles to diffuse into tumors and become held in place, or actively -- adding a targeted anti-cancer molecule to bind to specific cancer cell receptors and, in theory, keep the nanoparticle in the tumor longer. Now, new research on human and mouse tumors in mice by investigators at the Johns Hopkins Kimmel Cancer Center suggests the question is even more complicated. (2020-03-26)

Trastuzumab deruxtecan shows early promise in patients with non-breast/gastric cancers
A HER2-targeted antibody-drug conjugate, fam-trastuzumab deruxtecan-nxki (Enhertu), showed signs of clinical activity in multiple non-breast/non-gastric cancer types, according to results from a phase I study. (2020-03-25)

Statins may protect against the heart harms of breast cancer therapies
Statins are widely used to lower cholesterol and prevent heart disease and related deaths, but can they also help guard against heart damage caused by certain breast cancer therapies? New research being presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC) suggests the answer may be yes. (2020-03-19)

Protecting DNA origami for anti-cancer drug delivery
Scientists coated octahedral-shaped DNA origami with peptoids that help protect the nanostructures in physiological environments relevant to biomedical applications including anti-cancer drug delivery. (2020-03-09)

New drug combination could support better cancer treatments
Researchers have identified a promising new drug combination that could significantly help the immune system target cancer cells and kill them. (2020-03-05)

NCI-MATCH: T-DM1 shows promising activity in salivary gland cancer
A discovery from NCI-MATCH, the largest precision medicine cancer trial, relates to patients with salivary gland cancer treated with ado-trastuzumab emtansine (T-DM1), a drug already FDA-approved for certain types of breast cancer. Two of the three NCI-MATCH patients with this rare disease saw their tumors shrink by at least 30% with T-DM1 treatment and the benefit lasted two years for one patient and nine months for the other. Another recent trial reported similar benefits. (2020-01-07)

Obesity is a risk factor for cardiotoxicity in chemotherapy-treated patients with breast cancer
A recent study showed that being overweight or obese was a risk factor for cardiotoxicity in chemotherapy-treated patients with breast cancer, but it did not take into account related cardiac risk factors or other classic risk factors of cardiotoxicity produced by anthracycline and trastuzumab. In a study published Dec. 23 in the open-access journal PLOS Medicine, Elisé Kaboré of Centre Georges-François Leclerc and Charles Guenancia of University Hospital, Dijon, France, and colleagues address this gap in knowledge. (2019-12-23)

Mayo Clinic researchers present findings at the 2019 San Antonio Breast Cancer Symposium
Mayo Clinic researchers will present findings at the San Antonio Breast Cancer Symposium Dec. 10-14 in San Antonio. (2019-12-13)

Adding tucatinib to drug combination extends survival for advanced HER2+ breast cancer patients
Researchers from The University of Texas MD Anderson Cancer Center today reported study results showing the addition of tucatinib to capecitabine (Xeloda) and trastuzumab (Herceptin) significantly improved progression-free survival (PFS) and overall survival (OS) in patients with advanced HER2-positive breast cancer, with and without brain metastasis according to results of the HER2CLIMB clinical trial. (2019-12-11)

Tucatinib 'game changing' against HER2+ breast cancer, especially with brain metastases
Phase III results at NEJM and SABCS: Adding tucatinib to standard of care treatment nearly tripled one-year progression-free survival. (2019-12-11)

Biosimilar for HER2+ breast cancer: Overall response rate matches reference trastuzumab
The trastuzumab biosimilar HLX02 achieved similar overall response rate to reference trastuzumab in women with human epidermal growth factor receptor 2-positive (HER2+) recurrent or previously untreated metastatic breast cancer, according to a large, randomised phase III study reported at the ESMO Asia 2019 Congress. (2019-11-22)

Study finds key metabolic changes in patients with chemotherapy-associated cardiotoxicity
Researchers at Beth Israel Deaconess Medical Center embarked on a study to investigate whether early changes in energy-related metabolites in the blood -- measured shortly after chemotherapy -- could be used to identify patients who developed heart toxicity at a later time. (2019-07-18)

Two-in-one drug combining Herceptin with chemotherapy keeps women's breast cancers at bay
Guiding chemotherapy to a tumor by attaching it to the antibody-based target drug Herceptin (trastuzumab) is effective at treating women with breast cancer who have no other treatment options, a new clinical trial shows. The two-in-one treatment kept breast cancer at bay in women with a type of the disease called HER2-positive breast cancer who had stopped responding to existing drugs. (2019-06-27)

De-escalating breast cancer therapy; can some patients be spared chemotherapy?
Researchers develop molecular testing to distinguish patients who may need less from those who may need more therapy for HER2 positive breast cancer. (2019-06-25)

DNA nanorobots target HER2-positive breast cancer cells
According to the Mayo Clinic, about 20% of breast cancers make abnormally high levels of a protein called human epidermal growth factor receptor 2 (HER2). When displayed on the surface of cancer cells, this signaling protein helps them proliferate uncontrollably and is linked with a poor prognosis. Now, researchers have developed a DNA nanorobot that recognizes HER2 on breast cancer cells, targeting them for destruction. They report their results in the ACS journal Nano Letters. (2019-06-05)

'I'm here for breast cancer. Why are you talking to me about my heart?'
Many physicians are not telling cancer patients about the cardiotoxicity risks of treatments and may not be fully aware of the dangers themselves. A new study reveals an urgent need to look after the hearts of these patients. The research is presented today at EuroHeartCare 2019, a scientific congress of the European Society of Cardiology. (2019-05-04)

HER2 positive breast cancer: Treatment de-escalation needs to be personalized
De-escalation approaches in the treatment of women with HER2 positive breast cancer need to be personalized, according to Dr. Carmen Criscitiello, European Institute of Oncology, Milan, Italy. Her comments come on the occasion of the presentation of updated research results at the inaugural ESMO Breast Cancer Congress 2019, May 2-4, 2019, in Berlin, Germany. (2019-05-01)

Simple and fast method for radiolabelling antibodies against breast cancer
Radioactive antibodies that target cancer cells are used for medical diagnostics with PET imaging or for targeted radioimmunotherapy. Researchers from the University of Zurich have created a new method for radiolabelling antibodies using UV light. In less than 15 minutes, the proteins are ready-to-use for cancer imaging or therapy. (2019-04-23)

Patients resistant to breast cancer therapy show epigenetic differences
According to a new study, breast cancer patients who don't respond to targeted therapy have different patterns of epigenetic modifications than patients who do respond. Epigenetic modifications change gene expression without altering the DNA's genetic code. (2019-04-06)

Surgery associated with increased survival for patients with HER2+ stage 4 breast cancer
Surgery was associated with higher survival rates for patients with HER2-positive (HER2+) stage 4 breast cancer compared with those who did not undergo surgery, according to results presented at the AACR Annual Meeting 2019, March 29-April 3. (2019-04-02)

HER2-targeted CAR T-cell therapy shows promising antitumor activity in patients with sarcoma
A combination of chemotherapy and chimeric antigen receptor (CAR) T cells designed to target the protein HER2 was found to be safe and showed clinical responses in pediatric and adult patients with advanced HER2-positive sarcoma, according to results from a phase I clinical trial presented at the AACR Annual Meeting 2019, March 29-April 3. (2019-03-31)

Drug could alleviate side effects of chemo for breast cancer patients
Researchers at the Stanford University School of Medicine have demonstrated a method of forecasting which breast cancer patients will suffer heart problems from a commonly used chemotherapy drug. (2019-03-14)

The importance of sex-specific strategies for prevention, treatment of heart failure in women
There are many important differences between women and men with heart failure, highlighting the importance of sex-specific strategies for prevention and treatment, according to three papers publishing today in JACC: Heart Failure. This special focus issue will explore heart failure in women. (2019-02-25)

PET scans show biomarkers could spare some breast cancer patients from chemotherapy
In an effort to further individualize therapy and avoid over-treating patients, researchers at the Johns Hopkins Kimmel Cancer Center report a new study using PET scans has identified a biomarker that may accurately predict which patients with one type of HER2-positive breast cancer might best benefit from standalone HER2-targeted agents, without the need for standard chemotherapy. (2019-02-21)

Breast cancer cells shifted into HER2 positive status with bold new strategy
One of the most effective breast cancer drugs, Herceptin, is only available to people whose tumors test HER2-positive. That's only one in five breast cancer patients. That could change with a new approach from Scripps Research. (2019-02-07)

Breast cancer patients who take heart drug with trastuzumab have less heart damage
Breast cancer patients who take a heart drug at the same time as trastuzumab have less heart damage, according to a study presented today at EuroEcho-Imaging 2018. (2018-12-05)

Phase III KATHERINE trial crossed early reporting boundary and met its primary endpoint
Substituting trastuzumab emtansine (T-DM1, Kadcyla) for adjuvant trastuzumab (Herceptin) in patients who had residual disease after receiving neoadjuvant chemotherapy and trastuzumab reduced the risk of developing an invasive recurrence of HER2-positive early-stage breast cancer by 50 percent, according to data from the phase III clinical trial KATHERINE presented at the 2018 San Antonio Breast Cancer Symposium. (2018-12-05)

Patients with cancers of the gullet, stomach and bowel respond well to new anti-HER2 drug
An antibody that binds simultaneously to two distinct regions of the HER2 receptor to block the growth of cancer cells has shown promising signs of anti-tumor activity in a number of cancers including those of the gullet (esophagus), stomach and bowel. (2018-11-13)

Will tarloxotinib finally break the HER2 barrier in lung cancer?
By pairing a potent HER2/EGFR inhibitor with a targeting mechanism specific to tumors, researchers show that tarloxotinib is far more active against HER2 lung cancer cell lines than even the most successful existing HER2/EGFR inhibitors. (2018-11-07)

HER2+ early breast cancers where shorter-course trastuzumab could be an option
Women with HER2-positive early breast cancer with small tumours have similar disease-free survival and lower risk of cardiac toxicity with a nine-week course of adjuvant trastuzumab compared to those treated for one year, according to a subgroup analysis of the Short-HER trial reported at ESMO 2018 Congress in Munich. (2018-10-19)

Page 1 of 7 | 261 Results
   First   Previous   Next      Last   
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.